| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Completed Research
Forum: Help Conquer Cancer
Thread: Interesting News Articles About Cancer |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 954
|
|
| Author |
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges: 
|
http://www.medicalnewstoday.com/releases/262832.php
"Article Date: 04 Jul 2013 Scientists Determine Novel Regulation Of Metabolic Pathways In Cancer Cancer cells have alterations in metabolic pathways as a result of oncogenes that promote tumor growth. NRF2 (nuclear factor erythroid-derived 2-related factor 2) works as a "master gene" that turns on stress response by increasing numerous antioxidants and pollutant-detoxifying genes to protect the lungs from variety of air pollutants such as diesel exhaust and cigarette smoke. However, researchers at the Johns Hopkins Bloomberg School of Public Health and others have found for the first time that NRF2 signaling also plays a role in the growth of tumor cells by altering metabolic pathways. The study is published in the July issue of the Journal of Clinical Investigation..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/262837.php
"Article Date: 04 Jul 2013 Shut Down Of Cell Survival Process Found To Influence Fate Of Lung Cancer Tumors New research from Rutgers Cancer Institute of New Jersey, Princeton University and other collaborators suggests that inactivation of an essential gene responsible for the cell survival process known as autophagy can suppress the growth of non-small-cell lung cancer tumors and render them more benign. The findings suggest a possible role for autophagy blockers in the treatment of this type of lung cancer, which has a five-year survival rate of only 30 to 50 percent for early-stage disease..." |
||
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges: 
|
Antiviral Drug May Extend Brain Cancer Survival, Researchers Say
----------------------------------------WEDNESDAY, Sept. 4 (HealthDay News) -- A drug used against a common virus may lengthen the lives of people with a deadly form of brain cancer, a preliminary study suggests. Writing in the Sept. 5 issue of the New England Journal of Medicine, researchers reported on 50 patients who were given the antiviral drug valganciclovir (Valcyte) to help treat glioblastoma. The cancer is the most common form of brain tumor in adults, and it carries a dismal prognosis -- with a typical survival of just over a year. These 50 patients, however, fared far better, researchers found. After two years, 62 percent were still alive. Of the 25 who took the antiviral continuously, 90 percent were still alive. That compared with just 18 percent of patients who received most of the same treatments -- including surgery and chemotherapy -- but did not take Valcyte. "These data are by far the best ever seen for these patients," said lead researcher Dr. Cecilia Soderberg-Naucler, of the Karolinska Institute in Stockholm, Sweden.   |
||
|
|
Coleslaw
Veteran Cruncher USA Joined: Mar 29, 2007 Post Count: 1343 Status: Offline Project Badges: 
|
Patients Share DNA for Cures
----------------------------------------"The databases are designed to collect DNA and other information from patients with hard-to-treat diseases. The material can be analyzed for certain genetic mutations and made available to scholars and pharmaceutical companies." http://online.wsj.com/article/SB10001424127887323342404579079453190552312.html     |
||
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges:
|
Personalized Cancer Vaccine Enter Phase I Trials
---------------------------------------- . . . The team first developed a porous polymer implant, made from the same material as biodegradable sutures and meshes. Then they infused the disk with a collection of three immune stimulants that recruit the immune cells, activate them, and imprint them with a chemical signature of the tumor that is targeted for destruction. The first of the three immune stimulants is a drug called leukine (also known as GM-CSF), which summons millions of dendritic cells, key immune cells, to enter the implant. The second is DNA that mimics viral and bacterial DNA and sends a danger signal that activates these cells. The third ingredient is the personalized part of the recipe: a combination of proteins made from the patients’ own tumor. It gives the dendritic cells the unique signature of that person’s tumor, which they share with the warrior T-cells. The “educated” T-cells are then primed to hunt and obliterate the tumor. . . |
||
|
|
pcwr
Ace Cruncher England Joined: Sep 17, 2005 Post Count: 10903 Status: Offline Project Badges:
|
----------------------------------------  |
||
|
|
Randzo
Senior Cruncher Slovakia Joined: Jan 10, 2008 Post Count: 339 Status: Offline Project Badges: 
|
Engineered molecules boost immune attack on cancer, researchers say
http://med.stanford.edu/ism/2013/june/sirp-0610.html http://www.pnas.org/content/110/27/11103.long |
||
|
|
twilyth
Master Cruncher US Joined: Mar 30, 2007 Post Count: 2130 Status: Offline Project Badges:
|
An old tricyclic antidepressant (imipramine - Tofranil) seems to be effective against small cell lung cancer - even if the cells have become resistant to traditional chemo.
----------------------------------------Follow-up experiments showed that the tricyclic antidepressant called imipramine (Tofranil), was effective against human small cell lung cancer cells grown in the laboratory and growing as tumors in mice. The drug activated a self-destruction pathway in the cancer cells and slowed or blocked the spread of cancer in mice. More at link.Imipramine maintained its effectiveness regardless of whether the cancer cells had previously been exposed, and become resistant, to traditional chemotherapy treatments, according to the study, which was published online Sept. 27 in the journal Cancer Discovery. Because tricyclic antidepressants already have U.S. Food and Drug Administration approval for use in people, the Stanford team was quickly able to launch a clinical trial to test imipramine in patients with small cell lung cancer and certain other types of cancer. They are currently recruiting patients for the phase-2 trial. . . . . . . Another drug, an antihistamine called promethazine (Phenergan), also exhibited the ability to kill cancer cells, according to the researchers. [Edit 1 times, last edit by twilyth at Sep 27, 2013 10:50:37 PM] |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 669 Status: Offline Project Badges:
|
Survival After Cancer Diagnosis Strongly Associated With Governments Spending
The more an EU (European Union) national government spends on health, the fewer the deaths after a cancer diagnosis in that country, according to new research to be presented to the 2013 European Cancer Congress (ECC2013) and published simultaneously in the leading cancer journal Annals of Oncology. http://tinyurl.com/kejug6f  |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 669 Status: Offline Project Badges:
|
The War on Cancer: From Nixon Until Now
----------------------------------------When President Nixon signed the National Cancer Act many expected quick results; comparing the effort to the one that put man on the moon. After 42 years, what progress have we made? This New York Times video explores this question. http://tinyurl.com/lolo3v8 [Edit 1 times, last edit by Jim Slade at Nov 18, 2013 4:48:48 PM] |
||
|
|
|